Cepheid Reports 24 Percent Spike in Q3 Revenues | GenomeWeb

NEW YORK (GenomeWeb News) – Cepheid reported after the market closed on Thursday that its third quarter revenues increased 24 percent year over year.

The Sunnyvale, Calif.-based molecular diagnostics firm reported total revenues of $100.1 million for the three months ended Sept. 30, compared to $80.5 million for the third quarter of 2012. It exceeded the consensus analysts' estimate of $93.9 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: mutations linked to nasopharyngeal carcinoma, salivary proteins common among oral squamous cell carcinoma patients, and more.

At Wired, a science journalist discusses her decision not to undergo BRCA testing.

The Japan Times says regulations are needed to oversee human genome-editing research.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.